Your session is about to expire
← Back to Search
Arm 2 (SBRT + maintenance chemotherapy) for Non-Small Cell Lung Cancer
Study Summary
This trial is studying giving maintenance chemotherapy with or without local consolidation therapy to see if it works better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any openings for individuals to participate in this research?
"As indicated on clinicaltrials.gov, this research is no longer recruiting patients; the trial was originally posted in April 2017 and updated most recently in December 2023. However, 1938 other medical trials are actively looking for participants at present."
What number of medical facilities are now carrying out this clinical trial?
"There are 306 sites where this clinical trial is running, including West virginia University Healthcare in Morgantown, Langlade Hospital and Cancer Center in Antigo, and Lancaster General Ann B Barshinger Cancer Institute in Lancaster. Additionally there numerous other locations participating."
What is the current regulatory status of Arm 2 (SBRT + maintenance chemotherapy)?
"Although Phase 2 trials have only provided evidence of safety, our team at Power believes that Arm 2 (SBRT + maintenance chemotherapy) is relatively secure and assigned it a score of two."
What are the stated objectives of this experiment?
"The primary objective of this Phase III trial is to monitor Overall Survival. Secondary endpoints include the Time to Development of New Lesions, Time to In-Field Failure, and Incidence of Adverse Events graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 5. These measurements will be taken over a three year period on an intent-to-treat basis from randomization until documented progression or death due to any cause occurs first."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger